All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia

October 11th 2024

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

October 11th 2024

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Treatment Personalization Is Poised to Define New Era of mCRC Therapy

October 11th 2024

A panel of clinicians in the CRC field discussed findings from pivotal clinical trials that were primarily shared during the 2024 ASCO Annual Meeting.

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

October 11th 2024

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

October 11th 2024

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

FDA Approves Inavolisib Plus Palbociclib/Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer

October 10th 2024

The FDA approved inavolisib plus palbociclib/fulvestrant for select PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

October 10th 2024

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

Enfortumab Vedotin Plus Pembrolizumab Stands Strong as the Frontline Bladder Cancer SOC

October 10th 2024

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Fox Chase Cancer Center’s Daniel J. Campbell Receives Crystal Eagle Leadership Award From American Society for Healthcare Engineering

October 10th 2024

Daniel J. Campbell, TBE, CHFM, FASHE, received the Crystal Eagle Leadership Award from the American Society for Healthcare Engineering.

Talazoparib Plus Enzalutamide Improves OS in mCRPC

October 10th 2024

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

October 10th 2024

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Molecularly Targeted Therapeutics Are Precisely Aimed

October 10th 2024

Maurie Markman, MD, details how the precision-medicine paradigm is a highly rational platform for antineoplastic drug development.

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm

October 10th 2024

Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

October 10th 2024

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.

2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases

October 9th 2024

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 9th 2024

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI Cancers

October 9th 2024

OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.